Navigation Links
Genesis Biosciences Announces New Hire and Promotions on Operational and Scientific Staff
Date:9/21/2011

ved a B.S. in biology from The Ohio State University.

Prasanth Maddipati, Fermentation Scientist

Prasanth Maddipati joins Genesis with a solid background in bioprocess engineering, including the design and execution of microbial fermentation processes. At Genesis, he plays an important role in the monitoring and optimization of the company's fermentors and fermentation operations to help ensure accuracy and quality control. Prior to joining Genesis, Maddipati was a graduate research assistant at Oklahoma State University where he worked on fermentation of syngas to ethanol and other value-added products using a novel microbial catalyst. Maddipati has authored several publications in Bioresource Technology and has served as a panel speaker at leading biotechnology and bioengineering conferences. Maddipati received a B.Tech in industrial biotechnology from Anna University in India and an M.S. in biosystems engineering from Oklahoma State University.

Genesis Biosciences was formed in 2009 when United Kingdom-based Biotal Technologies and Lawrenceville, Georgia-based Genesis Technologies were first acquired and then merged by the CKM Group. Genesis Biosciences is a market leader in bacteria fermentation and is the first company to develop, manufacture and offer both microbial and antimicrobial products. Based on the knowledge and experience of the company's scientists and lab technicians, the company utilizes its in-house fermentation equipment and facilities to grow bacteria to the highest quality known in the marketplace. Additionally, Genesis creates solutions for the safe and natural eradication of bacteria using plant oils, essential oils and green chemistry.

About Genesis Biosciences

Genesis Biosciences is a biotechnology company specializing in bacteria fermentation, microbial, antimicrobial and environmentally preferred products and services. The company focuses its efforts on the development of diverse quality-a
'/>"/>

SOURCE Genesis Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Regenesis Biomedical Announces Additions to Board of Directors
2. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal 2008 on September 9, 2008
3. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
4. ThermoGenesis Reports Record Quarterly Revenues of $7.2 Million; Full Year Revenues Increase 31 Percent
5. ThermoGenesis Announces Distribution Agreement for Bone Marrow Stem Cell Device
6. ThermoGenesis Corp. to Announce First Quarter Fiscal 2009 Results on November 6, 2008
7. Genesis Pharmaceuticals Launches New Corporate Website
8. ThermoGenesis Presentation at Rodman & Renshaw Conference
9. Cardiogenesis Reports Third Quarter 2008 Results
10. Tissue Genesis Applies CE Mark to Its Adult Stem Cell Isolation System
11. Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... (PRWEB) August 20, 2014 High ... and apply the most complete climate and Earth ... demanding climate change issues. , Eight national laboratories, ... with the National Center for Atmospheric Research, four ... new effort. Other participating national laboratories include Argonne, ...
(Date:8/20/2014)...  PAREXEL International Corporation (NASDAQ: PRXL ) ... Baird Healthcare Conference in New York.  Ingo Bank ... be making a presentation on PAREXEL and discussing business ... 2014. A live webcast of the discussion ... website at www.PAREXEL.com in the Upcoming Events ...
(Date:8/20/2014)... August 20, 2014 Not long ago, ... studies should be performed late in the development cycle ... But current regulatory trends suggest that, like many things ... rise. In recent years, multiple drug sponsors have been ... address specific questions during phase I/II. It’s not only ...
(Date:8/20/2014)... improve the health of your heart, researchers have discovered. ... a standard TENS machine like those designed to relieve ... the small raised flap at the front of the ... The stimulation changed the influence of the nervous system ... can drive failing hearts too hard. , Professor Jim ...
Breaking Biology Technology:New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3PAREXEL International To Present At Baird Healthcare Conference 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2'Tickling' your ear could be good for your heart 2
... Switzerland, March 13 Arpida Ltd,(SWX: ARPN) announced today ... 2007 highlights, Major pipeline progress:, - ... cSSSI,achieves its pre-specified primary endpoint, as did the first, ... intravenous iclaprim in,cSSSI initiated, - First patients enrolled ...
... Innocoll, Inc., a,privately-held biopharmaceutical company, announced ... phase 2 clinical trials sponsored by its ... CollaRx(R),BUPIVACAINE SURGICAL IMPLANT for the management of ... SURGICAL IMPLANT is a biodegradable and fully,bioresorbable ...
... 13 Kansas has long,been known for its ... many have not realized, however, is that Kansas, ... far beyond the farm,-- namely, the scientific laboratory., ... and the,animal-health industry have positioned the state squarely ...
Cached Biology Technology:Arpida Announces Full Year 2007 Financial Results 2Arpida Announces Full Year 2007 Financial Results 3Arpida Announces Full Year 2007 Financial Results 4Arpida Announces Full Year 2007 Financial Results 5Arpida Announces Full Year 2007 Financial Results 6Arpida Announces Full Year 2007 Financial Results 7Arpida Announces Full Year 2007 Financial Results 8Arpida Announces Full Year 2007 Financial Results 9Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 2Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 3Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 4Op-Ed: The NBAF Would Build on Kansas' Existing Strengths in Bioscience 2
(Date:8/20/2014)... in this image of the Para and Mato Grosso ... likely intentionally set in order to deforest the land. ... of trees where the land is thereafter converted to ... forestland to farms, ranches, or urban use. The herringbone-patterned ... Amazon Rainforest in the middle of the image are ...
(Date:8/20/2014)... When are athletes who have suffered concussions ready to ... has found that high school athletes who head back ... experience a significant regression in their abilities to simultaneously ... as seen in changes in their balance and/or altered ... Ten of the 12 had returned to activity in ...
(Date:8/20/2014)... DENVER (August 20, 2014) Women who are poor ... to infants with elevated levels of the stress hormone, ... later in life, according to a new research from ... online recently in the American Journal of Human ... infants and relate it directly to the socioeconomic status ...
Breaking Biology News(10 mins):Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3CU Denver researcher shows economic disparities impact infant health 2
... rainforests are often called the "lungs of the planet" because ... But the amount of carbon dioxide that rainforests absorb, or ... a paper published online this week (Feb 6 2013) by ... from the University of Exeter, the Met Office-Hadley Centre and ...
... A closer look at personalized or point-of-care healthcare ... in India organized and chaired by NJIT Distinguished ... Medicine and Biology Society (EMBS) International Special Topic ... the world, focused on topics ranging from 21st ...
... Virginia Commonwealth University Massey Cancer Center suggest that a ... potentially be an effective new therapy for several forms ... and mantle cell lymphoma (MCL). The study, ... showed that the experimental drug combination killed cancer cells ...
Cached Biology News:Lungs of the planet reveal their true sensitivity to global warming 2Personalized health care will revolutionize 21st century medicine, says NJIT professor 2Personalized health care will revolutionize 21st century medicine, says NJIT professor 3Experimental drug combination selectively destroys lymphoma cells 2
... sealed isolation chamber provides a safe, ... sterile pharmaceuticals, in accord with USP-797 ... 100 (ISO 5) cleanliness conditions in ... IV rod and tilt-up front panel ...
... siRNA Tracker Intracellular Localization Kit with ... forward approach to directly label and ... an efficient yet non-destructive manner, for ... and functional inhibition of target gene ...
... The Label IT siRNA Tracker Intracellular ... provides a straight forward approach to ... your design, in an efficient yet ... experiments. Subcellular localization and functional inhibition ...
Selective media for Salmonella...
Biology Products: